|
MEDICAL ADVOCATES
Adolescents
Teens   HAART/ART

General Reports           Adverse Events
Abacavir                       Guidelines
Atazanavir
Combivir
Darunavir
Elvitegravir
Etravirine
Lopinavir
Nelfinavir
Raltegravir
Tenofovir
Tipranavir
Adherence
HIV Management Main New/Newsworthy  Home Page  
Last Update: May 03, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
      Journal Papers, Abstracts, and Commentaries
 
 
Predictors of Highly Active Antiretroviral Therapy Utilization for Behaviorally HIV-1-Infected Youth:
Impact of Adult Versus Pediatric Clinical Care Site.
Agwu AL, Siberry GK, Ellen J,  et al
J Adolesc Health. 2012 May;50(5):471-7.
Abstract

"+CLICK": pilot of a web-based training program to enhance ART adherence among HIV-positive youth.
Shegog R, Markham CM, Leonard AD, et al
AIDS Care. 2011 Sep 8.
 Abstract

Piloting behavioral family systems therapy to improve adherence among adolescents with HIV:
A case series intervention study.
 Gray W, Janicke D, Fennell E,  et al
J Health Psychol. 2011 Mar 25|
 Abstract

A primary care level algorithm for identifying HIV-infected adolescents in populations
at high risk through mother-to-child transmission.
Ferrand RA, Weiss HA, Nathoo K, et al
Trop Med Int Health. 2010 Dec 22.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Enhanced CD8(+) T Cell Apoptosis in HIV-Infected Adolescents with Virologic
Failure on Protease Inhibitor-Based Therapy.
 Zuo J, Church J, Belzer M, et al 
AIDS Res Hum Retroviruses. 2010 May 27.
Abstract

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally
infected children and adolescents.
Patel K, Ming X, Williams PL, Robertson KR, et al  
AIDS. 2009 Sep 10;23(14):1893-901.
 Abstract

FULL-TEXT ARTICLE
 Pharmacotherapy of pediatric and adolescent HIV infection.
Schuval SJ.
 Ther Clin Risk Manag. 2009 Jun;5(3):469-84.
Paper

A WEEK- IN-REVIEW FEATURED REPORT
FULL-TEXT DOCUMENT
 Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
CDC, NIH, and HIV Medicine Association of the IDSA
MMWR April 10, 2009
Paper
 
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents:
the recommendations of the Thai AIDS Society (TAS) 2008.
 Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al 
J Med Assoc Thai. 2008 Dec;91(12):1925-35.
 Abstract
 
Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral
Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral Therapy.
Agwu A, Lindsey JC, Ferguson K, et al
AIDS Patient Care STDS. 2008 May 15.
 Abstract
 
Long-Term Effects of Highly Active Antiretroviral Therapy on CD4(+) Cell Evolution among
Children and Adolescents Infected with HIV: 5 Years and Counting.
Patel K, Hernán MA, Williams PL, et al
Clin Infect Dis. 2008 Apr 2
 Abstract
 
Virologic Response Using Directly Observed Therapy in Adolescents With HIV: An Adherence Tool.
Purdy JB, Freeman AF, Martin SC, et al
J Assoc Nurses AIDS Care. 2008 Mar-Apr;19(2):158-65.
 Abstract
 
Clinical Outcomes After an Unstructured Treatment Interruption in Children and Adolescents
With Perinatally Acquired HIV Infection.
Saitoh A, Foca M, Viani RM, et al  
Pediatrics. 2008 Mar;121(3):e513-21.
 Abstract
 
FULL TEXT ARTICLE
Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic
infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS
in Belo Horizonte, Minas Gerais State, Brazil.
Candiani TM, Pinto J, Cardoso CA, Carvalho IR, et al
Cad Saude Publica. 2007;23 Suppl 3:S414-23.
 Paper
 
Long-Term Observation of Adolescents Initiating HAART Therapy: Three-Year Follow-Up.
Flynn PM, Rudy BJ, Lindsey JC, et al
AIDS Res Hum Retroviruses. 2007 Oct;23(10):1208-1214.
 Abstract
 
Long-term Follow-up of 414 HIV-Infected Romanian Children and Adolescents Receiving
Lopinavir/Ritonavir-Containing Highly Active Antiretroviral Therapy.
Kline MW, Rugina S, Ilie M, et al 
Pediatrics. 2007 Apr 9;
Abstract

FULL TEXT ARTICLE
Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with
HIV attracted through mother-to-child transmission: case report.
Friman V, Gisslen M.
AIDS Res Ther. 2007 Feb 23;4:
Paper
 
       Conference Reports, Abstracts, and Posters
 
 
Immune activation and function in HIV+ adolescents on therapy
D. Haney, M. Betts, J. Sleasman, et al
 (6th IAS Conference)
 Abstract

Highly active antiretroviral therapy (HAART) switches and common adverse drug reactions in children and adolescents on HAART in children of God Relief Institute, Kenya: January 2005 to December 2009
N. Kusu, T. Osoba, R. Musoke, et al
(6th IAS Conference)
 Abstract

The problematic of adolescent antiretroviral treatment adherence
Z.-K. Alice, K. Sonia, C. Bernadette
(6th IAS Conference)
 Abstract

Starting Late and Stopping Early: Disparities in HAART Utilization for Behaviorally HIV-infected Youth
 A Agwu, R Rutstein, A Gaur,  et al
 (18 CROI)
 Abstract

POSTER
 Prevalence of Mutations Associated with Resistance to Antiretroviral Drugs in a Cohort of Perinatally
HIV-infected Children and Adolescents in the US, 2001 to 2007
 G Del Bianco, G Heresi, J Murphy,  et al
(16 CROI)
 PDF Poster     Abstract
 

Outcomes of HAART in a cohort of adolescents in Argentina
 Coll Cardenas P , Fink V,  Balinotti S.
 (4th IAS Conference)
 Abstract
 
The PACTG 1020A Protocol: Atazanavir with or without Ritonavir in HIV-infected Infants,
Children, and Adolescents
 R Rutstein, P Samson, J Kiser, et al
 (14 CROI)
 Abstract
 
Sustained Increased Thymic Output and Decreased Immune Activation in Children and
Adolescents with High Post-therapy Viral Loads while Receiving PI-containing ART
C Rodriguez, L Yin, M Morrow, et al
 (14 CROI)
 Abstract
 
Adiponectin, Leptin, and Antiretroviral Use in HIV-infected Children and Adolescents
MR Araneta, T Ciaraldi, R Henry,  S Spector
 (14 CROI)
 Abstract
 
POSTER
 Long-term Follow-up of 414 HIV-infected Romanian Children and Adolescents Receiving
Lopinavir/Ritonavir-containing HAART
 M Kline, S Rugina, M Ilie, et al
 (14 CROI)
 PDF Poster  Abstract

HAART in children and adolescents in Latin America: relationship between viral load and
clinical characteristics from the national institute of child health and human development
international site development initiative (NISDI) pediatric study
Oliveira R., Byrne J., Souza R., et al
 (XVI International AIDS Conference)
 Abstract

  
Abacavir
 
      Journal Papers, Abstracts, and Commentaries
 
 
Abacavir and Metabolite Pharmacokinetics in HIV-1-Infected Children and Adolescents.
 Cross SJ, Rodman JH, Lindsey JC, et al  
J Acquir Immune Defic Syndr. 2009 Mar 11
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Abacavir Pharmacokinetics During Chronic Therapy in HIV-1-Infected Adolescents and Young Adults.
 Sleasman J, Robbins B, Cross S, et al 
Clin Pharmacol Ther. 2008 Dec 30
 Abstract
Atazanavir
 
      Journal Papers, Abstracts, and Commentaries
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Population pharmacokinetics of atazanavir/r in HIV-1 infected children and adolescents.
 Foissac F, Blanche S, Dollfus C, et al  
 Br J Clin Pharmacol. 2011 Jun 8.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Atazanavir and Atazanavir/Ritonavir Pharmacokinetics in HIV-Infected Infants, Children,
and Adolescents.
 Kiser JJ, Rutstein RM, Samson P, et al
AIDS. 2011 May 21.
 Abstract

HIV-Infected Adolescents: Relationship Between Atazanavir Plasma Levels and Bilirubin
Concentrations.
 Nso AP, Larru B, Bellón JM,  et al
J Adolesc Health. 2011 Jan;48(1):100-2'
 Abstract

Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and
Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection - Study ATN056.
 Kiser JJ, Fletcher CV, Flynn PM, et al 
Antimicrob Agents Chemother. 2007 Nov 19;
Abstract

      Conference Reports, Abstracts, and Posters

  Population Pharmacokinetics of ATV/r in HIV-1+ Children and Adolescents
F Foissac S Blanche1, C Dollfus, et al
 (18 CROI)
 Abstract
Comivir
 
      Journal Papers, Abstracts, and Commentaries
 
 
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in
adolescents.
 Flynn PM, Rodman J, Lindsey JC, et al 
Antimicrob Agents Chemother. 2007 Oct;51(10):3516-22.
 Abstract

Intracellular Pharmacokinetics of Once vs. Twice Daily Zidovudine and Lamivudine in
Adolescents.
Flynn PM, Rodman J, Lindsey JC, et al 
Antimicrob Agents Chemother. 2007 Jul 30;
 Abstract
Darunavir
 
      Journal Papers, Abstracts, and Commentaries
 
  High Dose of Darunavir in Treatment-Experienced HIV-Infected Adolescent Results in Virologic
Suppression and Improved CD4 Cell Count.
Rakhmanina NY, Neely MN, Capparelli EV.
Ther Drug Monit. 2012 Apr 30.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced
children and adolescents
 Blanche S, Bologna R, Cahn P, et al 
AIDS. 2009 Aug 30
 Abstract

FULL-TEXT ARTICLE
 Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
 Neely M, Kovacs A.
 Ther Clin Risk Manag. 2009 Jun;5(3):595-615.
Paper

      Conference Reports, Abstracts, and Posters
 
 
POSTER
 Low Darunavir and Etravirine Exposure When Used in Combination in HIV+ Children and Adolescents
J King, R Yogev, A Wiznia, et al
 (19 CROI)
 PDF Poster     Abstract

24-week efficacy, safety, tolerability, and pharmacokinetics (PK) of darunavir/ritonavir (DRV/r) once daily (qd) in
treatment-naive adolescents aged 12 to < 18 years in DIONE
P. Flynn, S. Blanche, C. Giaquinto, et al
 (6th IAS Conference)
 Abstract

Safety and Efficacy of Darunavir Co-administered with Low-dose Ritonavir in Treatment-experienced
Children and Adolescents at Week 24
 R Bologna, S Rugina, P Cahn, et al
 (15th CROI)
 Abstract
Elvitegravir
 

      Conference Reports, Abstracts, and Posters

  Pharmacokinetics and Safety of Once-Daily Elvitegravir in HIV-infected Adolescents
 A Gaur, J Abadi, A Wiznia,  et al  
 (17th CROI)
 Abstract
Etravirine
 
      Journal Papers, Abstracts, and Commentaries
 
  Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected
children and adolescents.
 Königs C, Feiterna-Sperling C, Esposito S,  et al
AIDS. 2011 Dec 7
 Abstract

     Conference Reports, Abstracts, and Posters

 
POSTER
 Low Darunavir and Etravirine Exposure When Used in Combination in HIV+ Children and Adolescents
J King, R Yogev, A Wiznia, et al
 (19 CROI)
 PDF Poster     Abstract

Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6-17 years):
week 24 primary analysis of the phase II PIANO study
G. Tudor-Williams, P. Cahn, K. Chokephaibulkit, et al
 (6th IAS Conference)
 Abstract

Population pharmacokinetics of etravirine in HIV-1-infected treatment-experienced children and adolescents
(6-17 years): week 24 primary analysis of the phase II PIANO trial
T. Kakuda, B. Green, G. Morrish, et al
 ((6th IAS Conference)
 Abstract
Lopinavir
 
      Journal Papers, Abstracts, and Commentaries
 
  Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection.
Schenone E, Di Biagio A, Parisini A, et al
 J Chemother. 2012;24(1):56-8.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside
Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated
with Protease Inhibitors - Study PACTG P1038.
 Robbins BL, Capparelli EV, Chadwick EG, et al
Antimicrob Agents Chemother. 2008 Jul 14.
 Abstract
 
         Conference Reports, Abstracts, and Posters
 
  POSTER
 Protease genotypes in children and adolescents failing protease inhibitor (PI) -based antiretroviral therapy (ART) at the Botswana-Baylor Children's Clinical Centre of Excellence in Gaborone, Botswana
A. Gomila, B. Kirk, M. Tolle. et al
 6 th IAS Conference)
 Poster     Abstract
Nelfinavir
 
         Conference Reports, Abstracts, and Posters
 
  POSTER
 Protease genotypes in children and adolescents failing protease inhibitor (PI) -based antiretroviral therapy (ART) at the Botswana-Baylor Children's Clinical Centre of Excellence in Gaborone, Botswana
A. Gomila, B. Kirk, M. Tolle. et al
 6 th IAS Conference)
 Poster     Abstract
Raltegravir
 
     Journal Papers, Abstracts, and Commentaries
 
  A WEEK-IN-REVIEW FEATURED REPORT
Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type
1-infected Children and Adolescents.
Briz V, León-Leal JA, Palladino C,  et al
Pediatr Infect Dis J. 2012 Mar;31(3):273-277.
 Abstract

       Conference Reports, Abstracts, and Posters
 
  POSTER
Raltegravir In Children and Adolescents: The French Expanded Access Program
I Thuret, C Tamalet, V Reliquet, et al
(16 CROI)
PDF Poster     Abstract
 
  Safety and Efficacy of Darunavir Co-administered with Low-dose Ritonavir in Treatment-experienced
Children and Adolescents at Week 24
 R Bologna, S Rugina, P Cahn, et al
 Abstract
Tenofovir
 
      Journal Papers, Abstracts, and Commentaries
 
 
A WEEK-IN-REVIEW FEATURED REPORT
A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-Experienced Human Immunodeficiency
Virus-1 Infected Adolescents.
Negra MD, de Carvalho AP, de Aquino MZ, et al
 Pediatr Infect Dis J. 2012 Feb 1.
Abstract

FULL-TEXT PDF ARTICLE
 Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate
and protease inhibitors.
 Pontrelli G, Cotugno N, Amodio D,  et al
 BMC Infect Dis. 2012 Jan 23;12(1):18.
 Paper

A WEEK-IN-REVIEW FEATURED REPORT
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents
and Young Adults: A 60-Month Follow-Up Study.
Viganň A, Bedogni G, Manfredini V,  et al
Clin Drug Investig. 2011;31(6):407-15
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected
Children and Adolescents: A Report from 5 Years of Clinical Experience.
 Rosso R, Parodi A, Torrisi C, et al
AIDS Res Hum Retroviruses. 2010 Sep 28
 Abstract

Decreased bone mineral density with off-label use of tenofovir in children and adolescents
infected with human immunodeficiency virus.
Purdy JB, Gafni RI, Reynolds JC
J Pediatr. 2008 Apr;152(4):582-4.
 Abstract

Increased beta-2 Microglobulinuria in HIV-1-Infected Children and Adolescents Treated with
Tenofovir
Papaleo A, Warszawski J, Salomon R, et al
Pediatr Infect Dis J. 2007 Oct;26(10):949-951.
 Abstract
 
       Conference Reports, Abstracts, and Posters
 
 
Vitamin D3 Supplementation Decreases PTH in HIV-infected Youth Being Treated with TDF-containing
Combination ART: A Randomized, Double-blind, Placebo-controlled Multicenter Trial: Adolescent Trials
Network Study 063
 P Havens, R Hazra, C Stephensen, et al
(9 CROI)
 Abstract

Tenofovir population pharmacokinetics in HIV-infected children and adolescents
J. King,  R. Yogev, A. Wiznia,  et al
(11th Int Wkshop on Clin Pharm of HIV}
 PDF Abstract

POSTER
 Renal Safety of Highly Active Antiretroviral Therapy including Tenofovir in Vertically HIV-Infected
Youths: a 60-Months Longitudinal Study
 V Giacomet, G Bedogni, V Manfredin, et al
(17th CROI)
PDF Pester     Abstract

POSTER
 Safety of HAART including Tenofovir on Bone Health in Vertically HIV-infected Youths:
A 60-Month Longitudinal Study
 C Cerini, S Mora, G V Zuccotti, et al
(17th CROI)
 PDF Poster     Abstract

Long-term Effect of HAART Containing Tenofovir on Bone Mass in HIV-infected Children and Adolescents:
A 48-Month Longitudinal Assessment
 A Viganň, G Zuccotti, V Giacomet, et al
(16 CROI)
 Abstract
Tipranavir
 
      Journal Papers, Abstracts, and Commentaries
 
  Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children
and adolescents.
Salazar JC, Cahn P, Yogev R, et al
AIDS. 2008 Sep 12;22(14):1789-98.
 Abstract
 
       Conference Reports, Abstracts, and Posters
 
 
POSTER
 Efficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir
(APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study)
JC Salazar, P Cahn, C Giaquinto, et al
(XVII Int. AIDS Conference )
 PDF Poster

NEWS RELEASE
New data shows HIV therapy tipranavir (Aptivus) is effective and well tolerated in children
 Boehringer Ingelheim
August 04 2008
 News
HAART Adverse Events
 
Central Nervous System
 
       Conference Reports, Abstracts, and Posters
 
  POWERPOINT POSTER PRESENTATION
Impact of highly active antiretroviral therapy on the incidence of HIV-encephalopathy among
perinatally-infected children and adolescents
K Patel
 (XVII International AIDS Conference)
 Poster Presentation
 
Immune Reconstitution Inflammatory Syndrome
 
      Journal Papers, Abstracts, and Commentaries
 
  Immune Reconstitution Inflammatory Syndrome Associated With Progressive Multifocal
Leukoencephalopathy in a Perinatally Acquired Human Immunodeficiency Virus-Infected
Young Adult
Chong TW, Dieudonne A.
Pediatr Infect Dis J. 2007 Nov;26(11):1068-1070.
Abstract

Cutaneous

      Journal Papers, Abstracts, and Commentaries

  Cutaneous EBV-related lymphoproliferative disorder in a 15-year-old boy
with AIDS: an unusual clinical presentation.
Fardet L, Blanche S, Brousse N, et al.
J Pediatr Hematol Oncol 2002 Nov;24(8):666-9
 Abstract
 		  

Endocrine

Cushing's Syndrome

      Journal Papers, Abstracts, and Commentaries

 
Cushing Syndrome and Severe Adrenal Suppression Caused by Fluticasone and
Protease Inhibitor Combination in an HIV-Infected Adolescent.
St Germain RM, Yigit S, Wells L, et al 
AIDS Patient Care STDS. 2007 Jun;21(6):373-7.
Abstract

Ritonavir-Fluticasone Interaction Causing Cushing Syndrome in HIV-Infected Children
and Adolescents.
 Arrington-Sanders R, Hutton N, Siberry GK.
Pediatr Infect Dis J. 2006 Nov;25(11):1044-1048.
Abstract
 
Hepatic
 
      Journal Papers, Abstracts, and Commentaries
 
  Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy.
Gil AC, Lorenzetti R, Mendes GB, et al
Sao Paulo Med J. 2007 Jul;125(4):205-209.
 Abstract
 
Metabolic

      Journal Papers, Abstracts, and Commentaries

 
Evaluation of insulin resistance in a cohort of HIV-infected youth.
Rosso R, Parodi A, d'Annunzio G, Ginocchio F, et al  
Eur J Endocrinol. 2007 Nov;157(5):655-9.
 Abstract

Hyperinsulinemia induced by highly active antiretroviral therapy in an adolescent with
polycystic ovary syndrome who was infected with human immunodeficiency virus.
Vigano A, Manzoni P, Riva S,  et al.   
Fertil Steril 2003 Feb;79(2):422-3
 Abstract

Musculoskeletal

      Journal Papers, Abstracts, and Commentaries

  Bone measures in HIV-1 infected children and adolescents: disparity between quantitative
computed tomography and dual-energy X-ray absorptiometry measurements.
Pitukcheewanont P, Safani D, Church J, Gilsanz V.
Osteoporos Int. 2005 Feb 9;
Abstract

       Conference Reports, Abstracts, and Posters

 
Relationship between Low Bone Mass Measurements and Age in HIV-infected
Children and Adolescents on HAART
S Mora  , V Giacomet  , L Cafarelli , et al
 (12 CROI)
 Abstract

Oral

      Journal Papers, Abstracts, and Commentaries

  Candida Epiglottitis in an Adolescent with Acquired Immunodeficiency Syndrome.
Sharma N, Berman DM, Scott GB, Josephson G.
Pediatr Infect Dis J. 2005 Jan;24(1):91-92
 Abstract

HIV Management Main New/Newsworthy  Home Page  

Adolescent HIV/AIDS : HAART/ART